B. Waterhouse

发表

A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea mon

J. Davidson, S. Mcmorn, B. Waterhouse, 2007, Clinical therapeutics.

Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension

J. Koh, Y. Min, M. Kang, 2016, Yonsei medical journal.

Vitamin D Repletion in Korean Postmenopausal Women with Osteoporosis

J. Koh, Y. Min, M. Kang, 2016, Yonsei medical journal.

A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis

L. Fitzpatrick, Mathew Thomas, A. Kakar, 2015, Indian journal of endocrinology and metabolism.

Differential effect of β‐blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI

P. Raskin, J. McGill, G. Bakris, 2007, Diabetic medicine : a journal of the British Diabetic Association.

Improving metabolic control leads to better working memory in adults with type 2 diabetes.

C. Ryan, M. Strachan, M. Freed, 2006, Diabetes care.

Effects of the small molecule SIRT1 activator, SRT2104 on arterial stiffness in otherwise healthy cigarette smokers and subjects with type 2 diabetes mellitus

D. Newby, B. Frier, N. Mills, 2016, Open Heart.

Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study.

O. Sitbon, M. Hoeper, K. Olsson, 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Differential Effects of &bgr;-Blockers on Albuminuria in Patients With Type 2 Diabetes

P. Raskin, J. McGill, G. Bakris, 2005 .

Quality of Life, Safety and Efficacy Profile of Thermostable Flolan in Pulmonary Arterial Hypertension

M. Gomberg-Maitland, S. Provencher, A. Spezzi, 2015, PloS one.

Initial treatment with fixed‐dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes

J. Krebs, H. Chou, B. Waterhouse, 2008, Diabetes, obesity & metabolism.

Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile.

A. Madan, N. Reichek, G. Bakris, 2006, The American journal of cardiology.

Cardiovascular Effects of a Novel SIRT1 Activator, SRT2104, in Otherwise Healthy Cigarette Smokers

D. Newby, N. Mills, J. Langrish, 2013, Journal of the American Heart Association.

Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study*

J. Rosenstock, B. Goldstein, B. Waterhouse, 2005, Current medical research and opinion.

Cardiometabolic effects of a novel SIRT1 activator, SRT2104, in people with type 2 diabetes mellitus

D. Newby, B. Frier, N. Mills, 2017, Open Heart.

Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study*

B. Goldstein, B. Waterhouse, A. Cobitz, 2006, Current medical research and opinion.

Bayesian detection of potential risk using inference on blinded safety data

Saurabh Mukhopadhyay, Brian Waterhouse, Alan Hartford, 2018, Pharmaceutical statistics.

Effects of the small molecule SIRT1 activator, SRT2104 on arterial stiffness in otherwise healthy cigarette smokers and subjects with type 2 diabetes mellitus

D. Newby, B. Frier, N. Mills, 2016, Open Heart.